Translating Clinical Data Into Patient Care: CAR T-Cell Therapy in DLBCL and CLL - Episode 1
CAR-T in Second-Line DLBCL: When and for Whom?
Experts discuss the use of chimeric antigen receptor T-cell (CAR T) therapies, specifically axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), in the second-line setting for patients with diffuse large B-cell lymphoma (DLBCL), focusing on patient selection and treatment frequency.
Video Player is loading.
Video content above is prompted by the following:
In the second-line setting in DLBCL, we currently have axi-cel and liso-cel. How often and for which patients do you consider CAR T for specifically in the second-line settieng?
Related Content:
